Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: To analyze the chemotherapy regimens and outcomes of advanced gastric cancer (AGC) patients older than 70 years of age. Methods: Between May 2001 and October 2009, 1135 patients with metastatic or recurrent gastric cancer received palliative chemotherapy. Of these patients 56 (4.9%) were ≥70 years old and were analyzed retrospectively. Results: The median age at the time of first-line chemotherapy was 73 years (range, 70-85) and the median Charlson comorbidity index was 0 (0-5). In all 17 patients (30%) received surgery with curative or palliative intent; 43 (77%) were treated by doublet or triplet first-line chemotherapy regimens and 13 patients (23%) received single agent chemotherapy. Median progression-free survival for first-line chemotherapy was 3.97 months (95% CI 2.05-5.89) with an overall response rate of 26%. After the first-line chemotherapy, only 18 of 56 (32%) patients received second-line chemotherapy. The median overall survival (OS) was 12.4 months (95% CI 2.81-21.99). In multivariate analysis, receiving surgery and disease control for first-line chemotherapy were independent prognostic factors for increased OS for all 56 patients. Conclusion: Patients older ≥70 years with metastatic or recurrent gastric cancer might achieve clinical benefit from chemotherapy. Receiving surgery and response of over more stable disease for first-line chemotherapy were independent prognostic factors for increased OS.

Original languageEnglish
Pages (from-to)194-200
Number of pages7
JournalAsia-Pacific Journal of Clinical Oncology
Volume8
Issue number2
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Disease-Free Survival
Comorbidity
Multivariate Analysis

Keywords

  • Chemotherapy
  • Elderly patients
  • Gastric cancer

ASJC Scopus subject areas

  • Oncology

Cite this

@article{f24fd99845714bd496589094cb48797c,
title = "Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?",
abstract = "Aim: To analyze the chemotherapy regimens and outcomes of advanced gastric cancer (AGC) patients older than 70 years of age. Methods: Between May 2001 and October 2009, 1135 patients with metastatic or recurrent gastric cancer received palliative chemotherapy. Of these patients 56 (4.9{\%}) were ≥70 years old and were analyzed retrospectively. Results: The median age at the time of first-line chemotherapy was 73 years (range, 70-85) and the median Charlson comorbidity index was 0 (0-5). In all 17 patients (30{\%}) received surgery with curative or palliative intent; 43 (77{\%}) were treated by doublet or triplet first-line chemotherapy regimens and 13 patients (23{\%}) received single agent chemotherapy. Median progression-free survival for first-line chemotherapy was 3.97 months (95{\%} CI 2.05-5.89) with an overall response rate of 26{\%}. After the first-line chemotherapy, only 18 of 56 (32{\%}) patients received second-line chemotherapy. The median overall survival (OS) was 12.4 months (95{\%} CI 2.81-21.99). In multivariate analysis, receiving surgery and disease control for first-line chemotherapy were independent prognostic factors for increased OS for all 56 patients. Conclusion: Patients older ≥70 years with metastatic or recurrent gastric cancer might achieve clinical benefit from chemotherapy. Receiving surgery and response of over more stable disease for first-line chemotherapy were independent prognostic factors for increased OS.",
keywords = "Chemotherapy, Elderly patients, Gastric cancer",
author = "Kim, {Seung Tae} and Park, {Kyong Hwa} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Shin, {Sang Won} and Kim, {Jun Suk} and Kim, {Yeul Hong}",
year = "2012",
month = "6",
day = "1",
doi = "10.1111/j.1743-7563.2011.01501.x",
language = "English",
volume = "8",
pages = "194--200",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?

AU - Kim, Seung Tae

AU - Park, Kyong Hwa

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Shin, Sang Won

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Aim: To analyze the chemotherapy regimens and outcomes of advanced gastric cancer (AGC) patients older than 70 years of age. Methods: Between May 2001 and October 2009, 1135 patients with metastatic or recurrent gastric cancer received palliative chemotherapy. Of these patients 56 (4.9%) were ≥70 years old and were analyzed retrospectively. Results: The median age at the time of first-line chemotherapy was 73 years (range, 70-85) and the median Charlson comorbidity index was 0 (0-5). In all 17 patients (30%) received surgery with curative or palliative intent; 43 (77%) were treated by doublet or triplet first-line chemotherapy regimens and 13 patients (23%) received single agent chemotherapy. Median progression-free survival for first-line chemotherapy was 3.97 months (95% CI 2.05-5.89) with an overall response rate of 26%. After the first-line chemotherapy, only 18 of 56 (32%) patients received second-line chemotherapy. The median overall survival (OS) was 12.4 months (95% CI 2.81-21.99). In multivariate analysis, receiving surgery and disease control for first-line chemotherapy were independent prognostic factors for increased OS for all 56 patients. Conclusion: Patients older ≥70 years with metastatic or recurrent gastric cancer might achieve clinical benefit from chemotherapy. Receiving surgery and response of over more stable disease for first-line chemotherapy were independent prognostic factors for increased OS.

AB - Aim: To analyze the chemotherapy regimens and outcomes of advanced gastric cancer (AGC) patients older than 70 years of age. Methods: Between May 2001 and October 2009, 1135 patients with metastatic or recurrent gastric cancer received palliative chemotherapy. Of these patients 56 (4.9%) were ≥70 years old and were analyzed retrospectively. Results: The median age at the time of first-line chemotherapy was 73 years (range, 70-85) and the median Charlson comorbidity index was 0 (0-5). In all 17 patients (30%) received surgery with curative or palliative intent; 43 (77%) were treated by doublet or triplet first-line chemotherapy regimens and 13 patients (23%) received single agent chemotherapy. Median progression-free survival for first-line chemotherapy was 3.97 months (95% CI 2.05-5.89) with an overall response rate of 26%. After the first-line chemotherapy, only 18 of 56 (32%) patients received second-line chemotherapy. The median overall survival (OS) was 12.4 months (95% CI 2.81-21.99). In multivariate analysis, receiving surgery and disease control for first-line chemotherapy were independent prognostic factors for increased OS for all 56 patients. Conclusion: Patients older ≥70 years with metastatic or recurrent gastric cancer might achieve clinical benefit from chemotherapy. Receiving surgery and response of over more stable disease for first-line chemotherapy were independent prognostic factors for increased OS.

KW - Chemotherapy

KW - Elderly patients

KW - Gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=84862786605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862786605&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2011.01501.x

DO - 10.1111/j.1743-7563.2011.01501.x

M3 - Article

VL - 8

SP - 194

EP - 200

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 2

ER -